A-769662 化学構造
分子量: 360.39

高品質保証

カスタマーフィードバック(4)

MSDS

製品説明

  • Compare AMPK Inhibitors
    AMPK製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 A-769662は一種の有効的で、可逆なAMPK活性剤で、無細胞試験でEC50値が0.8 μMになって、GPPase/FBPaseの活性にほとんど役立ちません。
ターゲット

AMPK

Fatty acid synthesis

IC50

0.8 μM

3.2 μM [1]

In vitro試験 A-769662 stimulates partially purified rat liver AMPK with EC50 with 0.8 μM. A-769662 activates AMPK purified from multiple tissues and species in a dose-responsive manner with modest variations in observed EC50s. EC50s determined for A-769662 using partially purified AMPK extracts from rat heart, rat muscle, or human embryonic kidney cells (HEKs) are 2.2 mM, 1.9 mM, or 1.1 mM, respectively. A 4 hours treatment of primary rat hepatocytes with A-769662 dose-dependently increases ACC phosphorylation, which correlated inhibition of fatty acid synthesis with IC50 of 3.2 μM. A-769662 also inhibits fatty acid sythesis in mouse hepatocytes with IC50 with 3.6 μM [1] A-769662 activates AMPK both allosterically and by inhibiting dephosphorylation of AMPK on Thr-172, similar to the effects of AMP. [2] A-769662 inhibits proteasomal function by an AMPK-independent mechanism. A-769662 affects the in vitro activity of purified 26S proteasomes but not the in vitro activity of purified 20S proteasomes. A-769662 has toxic effects on MEF cells. [3] A recent research shows A-769662 inhibited cell proliferation and DNA synthesis. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
mouse hepatocytes MWTGeY5kfGmxbjDhd5NigQ>? M4DuclEhdU1? Mn3SSG1UVw>? NHz1NIVqdmirYnn0d{Bn[XS2eTDhZ4llKHO7boTo[ZNqeyC5aYToJGlEPTBib3[gN{43KM7:TR?= MmTGNVY4PTN3N{[=
rat hepatocytes NIPnTnVHfW6ldHnvckBie3OjeR?= MoL5NUBuVQ>? MnHSSG1UVw>? MmXMbY5pcWKrdIOg[oF1fHliYXPp[EB{gW62aHXzbZMhf2m2aDDJR|UxKG:oIEOuOkDPxE1? MY[xOlc2OzV5Nh?=
HEK293 MnL1T4lv[XOnIHHzd4F6 M1K4bFIxOCEQvF2= NFTib3NFVVOR NGLzbZli[3SrdnH0[ZMh\W6mb3flco92eyCDTWDL MVyxO|czQDJ2MR?=
CCL13 MnPRT4lv[XOnIHHzd4F6 NGnW[lMzODBizszN MoDzSG1UVw>? M3vk[YFkfGm4YYTld{BmdmSxZ3Xuc5V{KEGPUFu= MknSNVc4Ojh{NEG=
MEFs M4W0eGZ2dmO2aX;uJIF{e2G7 MYKzNFAh|ryP MW\EUXNQ MoXTbY5pcWKrdIOgdJJwfGWjc3;tZYwh\nWwY4Tpc44h[nliYX6gRW1RUy2rbnTldIVv\GWwdDDt[YNp[W6rc32= MnfSNVg2QTN3OES=
epididymal clear cells MWLGeY5kfGmxbjDhd5NigQ>? MnTqNlAxKM7:TR?= NXWyWXBSTE2VTx?= M4nTeYlvcGmkaYTzJJRp\SCySD3t[YRq[XSnZDDWMWFVWGG|ZTDhZ4N2dXWuYYTpc44h[XRidHjlJIFxcWOjbDDt[Y1jemGwZR?= M3PXfFE6OjFzOUG4
3T3-L1 NF3YbIJHfW6ldHnvckBie3OjeR?= MXOxMlIhdU1? NH\Qd2pFVVOR MYrpcohq[mm2czCzWFMuVDFiQXTpdI9o\W6nc3nz Mo\aNVk1QDN|MES=
3T3-L1 MXLGeY5kfGmxbjDhd5NigQ>? MlTjNU4zKG2P MX7EUXNQ NV;rRoJIcW6qaXLpeJMhfGinIFX4dJJme3Orb36gc4YhSWSrcH;n[Y5me2m|UnXsZZRm\CCWcnHud4NzcXC2aX;uJGZi[3SxcoOgZY5lKE2jcnvldpM> MVmxPVQ5OzNyNB?=
3T3-L1 MmXNSpVv[3Srb36gZZN{[Xl? M{DUSFEvOiCvTR?= MoLwSG1UVw>? NFTJXnJqdmirYnn0d{BOcXSxdHnjJGNtd26jbDDFfJBidnOrb36= NF;uXpAyQTR6M{OwOC=>
3T3-L1 MVLjfZRwfG:6aXPpeJkh[XO|YYm= NWToe3hYOS5{IH3N M2qwUmROW09? M{TXfYRm[3KnYYPld{BE\WyuIG\pZYJqdGm2eR?= NILhZ2oyQTR6M{OwOC=>
3T3-L1 M{DOZ2tqdmG|ZTDhd5NigQ>? MVWxMlIhdU1? Mn[5SG1UVw>? M3;TXIFkfGm4YYTld{BCVVCN NHf5NW0yQTR6M{OwOC=>
L6 skeletal muscle cells MnfpSpVv[3Srb36gZZN{[Xl? MX:yOVAh|ryP MV;EUXNQ NXvF[Jd4[WO2aY\heIV{KEGPUFugd4lodmGuaX7nJJBifGi5YYnz M2D2bVE6QDJ6OEO2
L6 skeletal muscle cells M3L0PGZ2dmO2aX;uJIF{e2G7 M4fKPVI2OCEQvF2= MUHEUXNQ MULpcohq[mm2czD0bIUhVmFtLVurMWFVWGG|ZTD0doFve3CxcoSgZYN1cX[rdImgZY5lKGOnbHygd5Vz\mGlZTDhZpVv\GGwY3W= NUP2XYlbOTl6Mki4N|Y>
MDA-MB231 MUXBdI9xfG:|aYOgZZN{[Xl? NID1co81ODBizszN NFrsT2VFVVOR NXSzfY8{e2Wwc3n0bZpmeyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hXFKDSVytbY5lfWOnZDDhdI9xfG:|aYO= Mn7jNVk5QTZ2Nkm=
BT474 NWfxZ|Z7SXCxcITvd4l{KGG|c3H5 NFe1RZA1ODBizszN NYq3Z2hyTE2VTx?= NYL3bIh4e2Wwc3n0bZpmeyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hXFKDSVytbY5lfWOnZDDhdI9xfG:|aYO= NIXVV44yQTh7NkS2PS=>
MCF7 NXX3S|BQSXCxcITvd4l{KGG|c3H5 MonkOFAxKM7:TR?= NIPSb|BFVVOR NGew[2Z{\W6|aYTpfoV{KGi3bXHuJIJz\WG|dDDjZY5k\XJiY3XscEBtcW6nczD0c{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orcx?= M37XPVE6QDl4NE[5
Mesenchymal stem cells M17aRWtqdmG|ZTDhd5NigQ>? MnPlNVAhyrWP MUHEUXNQ M2fYSolv\HWlZYOgZUBzd2K3c4SgZY5lKHO3c4ThbY5m\CCDTWDLJIFkfGm4YYTpc44> NV;6XFNtOjRzMES4O|k>
Mesenchymal stem cells NVfjVId5[3m2b4TvfIlkcXS7IHHzd4F6 NFz1U44yODBiwsXN NWTJSow4TE2VTx?= MljB[IVkemWjc3XzJJRp\SCPU1OgdJJwdGmoZYLheIlwdg>? NF;yemczPDFyNEi3PS=>
MG-63 MVLjfZRwfG:6aXPpeJkh[XO|YYm= MWexNEDDvU1? NEOzdYNFVVOR NFTDV5NqdmirYnn0d{BJOk9{LVnu[JVk\WRiT4P0[Y9jdGG|dDDD[YxtKESnYYTo MYCyOFk3ODN4Mh?=
MC3T3-E1 NW\KV2tF[3m2b4TvfIlkcXS7IHHzd4F6 M1rEVFExKML3TR?= MnfrSG1UVw>? MWDpcohq[mm2czDINm8zNUmwZIXj[YQhV3O2ZX;icIF{fCCFZXzsJGRm[XSq M2jRVVI1QTZyM{[y
MG-63 MV7BdI9xfG:|aYOgZZN{[Xl? MVqxNEDDvU1? NHvMUJBFVVOR MUfzeZBxemW|c3XzJGgzVzJvSX7keYNm\CCRc4Tlc4Jt[XO2IFPlcIwhSXCxcITvd4l{ NUjUelQxOjR7NkCzOlI>
MC3T3-E1 M13DdmFxd3C2b4Ppd{Bie3OjeR?= NIPUU4oyOCEEtV2= M1zaPGROW09? M3;TNZN2eHC{ZYPz[ZMhUDKRMj3JcoR2[2WmIF;zeIVw[myjc4SgR4VtdCCDcH;weI9{cXN? NHvyNHQzPDl4MEO2Ni=>
MG-63 NYG1ZVI3TnWwY4Tpc44h[XO|YYm= NE\WOWIyOCEEtV2= NXH2OoZ3TE2VTx?= MlS5ZYxt\X[rYYTld{BTV1NiYXPjeY12dGG2aX;uJIFv\CCDVGCg[IVxdGW2aX;uJINifXOnZDDifUBJOk9{ NXiy[ZczOjR7NkCzOlI>
MC3T3-E1 NI\VdZBHfW6ldHnvckBie3OjeR?= M3n2[FExKML3TR?= M{H4T2ROW09? MkH4ZYxt\X[rYYTld{BTV1NiYXPjeY12dGG2aX;uJIFv\CCDVGCg[IVxdGW2aX;uJINifXOnZDDifUBJOk9{ NHzkbXQzPDl4MEO2Ni=>
MG-63 MoS0SpVv[3Srb36gZZN{[Xl? M4PmO|ExKML3TR?= MkDHSG1UVw>? NHribm5n[WOrbHn0ZZRmeyCKMl:yMYlv\HWlZXSgZZV1d3CqYXf5JIFkfGm4YYTpc44> NF;iSmEzPDl4MEO2Ni=>
MC3T3-E1 M2Tq[2Z2dmO2aX;uJIF{e2G7 M1PpbFExKML3TR?= MmrESG1UVw>? Mo\3[oFkcWyrdHH0[ZMhUDKRMj3pcoR2[2WmIHH1eI9xcGGpeTDhZ5RqfmG2aX;u MYiyOFk3ODN4Mh?=
PC3 MkSwT4lv[XOnIHHzd4F6 NHLaN2QyODBiwsXN MYrEUXNQ M1HER5VxemWpdXzheIV{KHSqZTDs[ZZmdHNib3[gRW1RUyCjbnSgRWNEKHCqb4PwbI9zgWyjdHnvci=> Mlj3NlU2QTRyNEO=
PC3M Mo\oT4lv[XOnIHHzd4F6 NI\yV5MyODBiwsXN NV;I[odnTE2VTx?= MnyweZBz\We3bHH0[ZMhfGinIHzleoVteyCxZjDBUXBMKGGwZDDBR2MheGixc4Doc5J6dGG2aX;u MVWyOVU6PDB2Mx?=
PC3 MkPZSpVv[3Srb36gZZN{[Xl? M{\4N|ExOCEEtV2= M4LkbmROW09? NYPhUIQ{cW6mdXPld{BRUTONL33UU3IheGG2aIfhfZM> NXu4VJJuOjV3OUSwOFM>
PC3M M3LXV2Z2dmO2aX;uJIF{e2G7 M1LLfVExOCEEtV2= NG\aNHFFVVOR NXWzfFVXcW6mdXPld{BRUTONL33UU3IheGG2aIfhfZM> MnHZNlU2QTRyNEO=
PC3 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGTkSFAyODBiwsXN NHWwbmJFVVOR NUfyenZPe3WycILld5NmeyCycn;sbYZmemG2aX;u NEXEdHQzPTV7NEC0Ny=>
PC3M MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXGxNFAhyrWP M3TY[GROW09? NHO5PFl{fXCycnXzd4V{KHC{b3zp[oVz[XSrb36= NFixc|QzPTV7NEC0Ny=>
MC3T3-E1 M{HOUmtqdmG|ZTDhd5NigQ>? NHu3eJcyOCEQvF2= M4DibWROW09? NUPBT4hDcW6mdXPld{B{cWewaX\pZ4FvfCCDTWDLJIFkfGm4YYTpc44> NFnWO3YzPjh7MUi2Oi=>
MC3T3-E1 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXLJTJBOOTBizszN NEK3NVZFVVOR NVj3cIZ1cW6qaXLpeJMhTGW6LXnu[JVk\WRib4P0[Y9jdGG|dDDj[YxtKGSnYYTo NWTaU4pSOjZ6OUG4OlY>
MC3T3-E1 NGnldodHfW6ldHnvckBie3OjeR?= MorUNVAh|ryP NW\yd|dYTE2VTx?= Mnq5bY5pcWKrdIOgSIV5NWmwZIXj[YQhd3irZHH0bZZmKHO2cnXzdy=> NX\rZYhFOjZ6OUG4OlY>

... Click to View More Cell Line Experimental Data

In vivo試験 Short-term treatment of normal Sprague Dawley rats with A-769662 decreases liver malonyl CoA levels and the respiratory exchange ratio, VCO2/VO2, indicating an increased rate of whole-body fatty acid oxidation. Treatment of ob/ob mice with 30 mg/kg b.i.d. A-769662 decreases hepatic expression of PEPCK, G6Pase, and FAS, lowers plasma glucose by 40%, reduced body weight gain and significantly decreases both plasma and liver triglyceride levels. [1]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

96-well AMPK assay AMPK activity is measured by monitoring phosphorylation of the SAMS peptide substrate (20 mM in standard assays and 100 mM in additivity assays) following a previously described protocol (Anderson et al., 2004). To determine whether A-769662-induced AMPK activation occurs in a reversible manner, AMP or A-769662 are preincubated with rat liver AMPK for 10 minutes at 20 times standard assay concentrations prior to dilution and measurement of AMPK activity.
Fatty Acid Synthesis Assay Primary rat hepatocytes are isolated and plated at 5 × 104 cells per well on BioCoat, collagen-coated, black-walled 96-well plates in DMEM supplemented with 10% FBS, 5 mM glucose, 1 mM sodium pyruvate, 2 mM L-glutamine, 25 mM HEPES, 0.1 m M nonessential amino acids, 5 μg/ml transferrin, 100 nM dexamethasone, 100 nM insulin and 25 μg/ml gentamycin. After 4 hr medium is replaced with medium as described above but without FBS and containing 100 nM triiodothyronine (T3). Following a 16 hr, 37°C incubation, the incubation medium is removed and replaced with medium containing 14C acetate (2 μCi/ml) and AICAR or test compounds at the indicated concentrations. Cells are incubated 4 hr at 37°C then the plates are rinsed with PBS. The final wash is replaced with Microscint20 and radioactivity incorporated into fatty acid monitors on a Wallac Microbeta plate reader.

細胞アッセイ:

[3]

細胞株 MEF cells
濃度 300 μM
反応時間 24 hours
実験の流れ

Cell viability of MEF cells treated or not with A-769662 is performed as follows: cells are harvested by trypsinization and incubated with 0.5 mg/mL RNase and 50 μg/mL propidium iodine at room temperature in the dark; cell viability is analyzed by flow cytometry using a FACScanto flow cytometer, using an excitation laser at 488 nm and a propidium iodine fluorescence detection at 600 nm. To determine the proportion of cells in each phase of the cell cycle, cells are harvested by trypsinization, collected by centrifugation, washed in PBS and fixed overnight in 80% ethanol at -20 °C. Subsequently, these fixed cells are centrifuged to remove the fixative and incubated for 20 minutes in the dark at room temperature in PBS containing 0.5 mg/mL RNase and 50 μg/mL propidium iodine. Flow cytometry analysis is performed as above. The proportion of cells in G1, S, and G2 is determined using the MODFIT program. Cell culture pictures are taken at the indicated times using a camera coupled to an inverted microscope with a 20 × objective.

動物実験:

[1]

動物モデル Sprague Dawley rats
製剤 A-769662 is dissolved in DMSO.
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download A-769662 SDF
分子量 360.39
化学式

C20H12N2O3S

CAS No. 844499-71-4
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 72 mg/mL (199.78 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Thieno[2,3-b]pyridine-5-carbonitrile, 6,7-dihydro-4-hydroxy-3-(2'-hydroxy[1,1'-biphenyl]-4-yl)-6-oxo-

文献中の引用 (6)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related AMPK 阻害剤

  • HTH-01-015

    HTH-01-015は一種の有効的で、選択性的なNUAK1阻害剤で、このIC50値が100 nMになって、NUAK1に作用する選択性がNUAK2に作用する選択性より100倍以上高くなります。

  • Dorsomorphin (Compound C, BML-275)

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β阻害剤で、IC50値が10 nM と6.7 nMに分かれます。

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • AICAR (Acadesine)

    AICAR (Acadesine)はZMPの蓄積を引き起こして、AMPがAMPKと AMPKキナーゼに刺激する作用のことを真似ます。臨床3期。

    Features:A potential first-in-class adenosine regulating agent (ARA).

  • Phenformin HCl

    Phenformin HClは一種のフェンホルミン(Phenformin)の塩酸塩で、一種のビグアナイド系(biguanide class)の抗糖尿病薬です。

  • Dorsomorphin 2HCl

    Dorsomorphin (Compound C) 2HCは一種の有効的で、可逆的で、選択性AMPK阻害剤で、無細胞試験でKi値が109 nMになって、若干の構造に関してのキナーゼ(ZAPK、SYK、PKCθ、PKAとJAK3を含める)に著しい抑制作用を表しませんが、I型BMP受容体も抑制します。

  • WZ4003

    WZ4003は一種の高特異性のNUAKキナーゼ阻害剤で、無細胞試験でNUAK1とNUAK2に作用する IC50値が20 nMと100 nMに分かれて、他の139種キナーゼに著しい阻害作用を表しません。

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。

最近チェックしたアイテム

Tags: A-769662を買う | A-769662供給者 | A-769662を購入する | A-769662費用 | A-769662生産者 | オーダーA-769662 | A-769662代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ